1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Physician Views: Five key diabetes market questions ahead of ADA 2014

Physician Views: Five key diabetes market questions ahead of ADA 2014

  • June 2014
  • ID: 2185198
  • Format: PDF
  • Firstword Pharma

Summary






This year's annual meeting of the American Diabetes Association (ADA) – which will take place June 13-17 in San Francisco – intersects the diabetes market at a notable point of evolution.

In the long-acting basal insulin market, the effective duopoly of Sanofi's Lantus and Novo Nordisk's Levemir appears to be reaching a conclusion. Over the next few years Lilly plans to launch one, or potentially two, therapies in this space; a novel insulin currently known as Peglispro which has demonstrated superior efficacy to Lantus and a biosimilar version of Sanofi's product which could be approved in Europe by the end of the year and in the US during 2016. In the same year, Novo Nordisk's Tresiba is widely expected to gain approval in the US, by which point Sanofi itself will likely have launched a successor product to Lantus now known as Toujeo.

See Physician Views Poll Results – Usage of Sanofi's U300 will not be limited to 'high-risk' Lantus patients, infer endocrinologists

Both Sanofi and Novo Nordisk will present data at ADA regarding Toujeo and Tresiba, respectively, which in each case will focus on how the new products are differentiated from Lantus, primarily in terms of hypoglycaemia control. Set against this backdrop of an evolving basal insulin market, Lilly's biosimilar Lantus data will receive great scrutiny, while investors and analysts will be looking to ascertain physician perception towards Lilly's Peglispro; another potentially superior insulin to Lantus but which retains some safety issues at this point.

In the oral diabetes market, there are two key trends to watch. In the GLP-1 agonist market, Eli Lilly and Boehringer Ingelheim's dulaglutide looks set to emerge as the most viable competitor to Novo Nordisk's market-leading Victoza franchise. Dulaglutide has demonstrated comparable efficacy to Victoza but reduced weight loss potential (see ViewPoints: ADA Preview - Eli Lilly's dulaglutide fails to match Victoza's weight-loss profile – can it still compete?). Nevertheless, it provides a dosing advantage via its once-weekly profile versus daily administration for Victoza. Closer examination of the dulaglutide is widely expected to be one of the key focal points at the ADA meeting.

Building on the stronger-than-expected launch of the SGLT-2 inhibitor class in 2013 (driven primarily by Johnson & Johnson's Invokana) there is also notable enthusiasm for the combination use of drugs in this class with DPP-4 inhibitors. Both AstraZeneca and Eli Lilly as well as Boehringer Ingelheim will present data on these combinations at ADA; topline data in abstract form demonstrates increased efficacy versus the separate component agents and has prompted analysts to suggest that market share could be gained at the expense of the GLP-1 agonist market owing to the oral dosing of these combinations.








With these factors in mind, FirstWord is polling US and EU5-based endocrinologists on five key questions ahead of the ADA meeting, Specifically we are asking them...


Whether they consider Eli Lilly's dulaglutide or Novo Nordisk's Victoza to have the best clinical profile based on currently available data
What level of end-user pricing discount they believe will be necessary to drive moderate uptake of Eli Lilly's biosimilar Lantus product
Their assessment of the commercial opportunity for Eli Lilly's peglispro in the basal insulin market based on currently available efficacy and safety data
Their anticipated peak usage of combination DPP-4/SGLT-2 inhibitor products
How they anticipate usage of these combinations may impact their prescribing of injectable GLP-1 agonists




Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.

ref:plp2014

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on